

Literaturverzeichnis

- [1] Balch, C. M., A. N. Houghton and L. J. Peters, *Cutaneous Melanoma*. In *Cancer. Principles & Practice of Oncology*. (Ed. V. T. DeVita, S. Hellman and S. A. Rosenberg) pp. 1612-1661, J.B.Lippincott Company, Philadelphia 1993.
- [2] Eggermont, A., U. R. Kleeberg, D. J. Ruiter and S. Suci, *European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b*. In *American Society of Clinical Oncology Educational Book*. (Ed. American Society of Clinical Oncology) pp. 88-93, Lippincott Williams & Wilkins, Baltimore, MD 2001.
- [3] Eggermont, A. M. M., U. R. Kleeberg, S. Suci and E.-B. Broecker, *The trial authors reply*. *Lancet Oncol* 2, 333-334 (2001).
- [4] Kiene, H., *EORTC mistletoe study*. *Lancet Oncol* 2, 333 (2001).
- [5] Kleeberg, U. R. Adjuvant trial in melanoma patients comparing rIFN- to rIFN- to Iscador to a control group after curative resection of high risk primary ($\geq 3\text{MM}$) or regional lymphnode metastasis (EORTC 18871). *European Journal of Cancer* 35[Suppl.4], S82. 1999.
- [6] Kleeberg, U. R., S. Suci, E. B. Bröcker, D. J. Ruiter, C. Chartier, D. Liénard, J. Marsden, D. Schadendorf and A. M. M. Eggermont, *Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-a2b versus rIFN-g versus Iscador M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3mm) or regional lymph node metastasis*. *Eur J Cancer* 40, 390-402 (2004).